Glycosmedia Weekly Diabetes News - 09/10/2021

Is it time to consider depression as a major complication of type 2 diabetes? Evidence from a large population-based cohort study

Our findings highlight that depression is associated with an increased risk for complications in type 2 diabetes and mortality and should not be neglected (Acta Diabetologica)

Basement membrane proteins in various arterial beds from individuals with and without type 2 diabetes mellitus: a proteome study

Our results suggest that accumulation of BM proteins is a general phenomenon in the medial layer of non-atherosclerotic arteries in patients with T2DM. Moreover, we identify additional T2DM-associated effects on the arterial proteome, which requires validation in future studies (Cardiovascular Diabetology)

Impact of COVID-19 lockdown on glycemic control in patients with type 1 and type 2 diabetes mellitus: a systematic review

Glycemic values in people with T1D significantly improved during COVID-19 lockdown, which may be associated with positive changes in self-care and digital diabetes management. In contrast, lockdown rather determined a short-term worsening in glycemic parameters in patients with T2D (Diabetology & Metabolic Syndrome)

Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials

Treatment with SGLT2 inhibitors improves liver structure and function in patients with T2D. This meta-analysis suggests that SGLT2 inhibitors are a promising pharmacological approach for treatment of NAFLD (Diabetes/Metabolism Research and Reviews)

Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy

This study introduces a dynamic and non-invasive assessment strategy for the underlying pathogenesis of diabetic peripheral neuropathy (Diabetologia)

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine

In patients with type 2 diabetes and preserved renal function treatment with M+I resulted in reduction of renal perfusion and increase in vascular resistance, in contrast to treatment with E+I that preserved renal perfusion and reduced vascular resistance (Cardiovascular Diabetology)

Type 2 diabetes in adults: management (update)

You can now review and comment on this draft guideline (NICE)

Type 2 diabetes in adults: management – SGLT2 inhibitors for chronic kidney disease (update)

You can now review and comment on this draft guideline (NICE)

Effect of Maternal Metformin Treatment in Pregnancy on Neonatal Metabolism: Evidence From Newborn Metabolic Screening

We have identified subtle (nonpathological) changes in neonatal metabolism that represent a signature effect of fetal metformin exposure (Diabetes Care)

Effects of Empagliflozin on Insulin Initiation or Intensification in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from the EMPA-REG OUTCOME® Trial

In patients with type 2 diabetes and cardiovascular disease, empagliflozin markedly and durably delays insulin initiation and substantial increases in insulin dose while facilitating sustained reductions in insulin requirements over time (Diabetes, Obesity and Metabolism)

Association of glycemic variability assessed by continuous glucose monitoring with subclinical diabetic polyneuropathy in type 2 diabetes

The SDgluc is a significant independent contributor to subclinical diabetic polyneuropathy, in addition to conventional risk factors including diabetes duration and HbA1c (Journal of Diabetes Investigation)